AAVXF:OTCMKTS
Abivax SA
139,00 US$
0,00%
(0,00) 1D
9 korr, 9:30:01 p.d., GMT-4 · USD
search
Të gjitha simbolet
| Me simbole | Çmimi | Ndrysho | % ndryshim |
|---|
insights_autoPo gjenerohen statistikat kryesore për AAVXF...
Kapitalizimi i tregut
6,63 mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
139,00 US$
Minimumi 52-javor
71,26 US$
Beta
3,09
Aksionet në qarkullim
87,53 mln
Numri i punonjësve
98
Kapitalizimi i tregut
6,63 mld
Vëllimi mesatar
0,00
Vëllimi
0,00
Maksimumi 52-javor
139,00 US$
Minimumi 52-javor
71,26 US$
Beta
3,09
Aksionet në qarkullim
87,53 mln
Numri i punonjësve
98
Lajmet
Nga burimet në ueb dhe partnerët e lajmeve
https://www.dars.gov.et/
·
5 ditë më parë
ABVX Q2 2026 Earnings: Wider-Than-Expected Loss as Pre-Revenue Biotech Keeps Spending on Pipeline
Profili
Abivax SA is a clinical stage biotechnology company focused on developing innovative treatments that harness the body’s natural regulatory mechanisms to modulate the immune response in patients with chronic inflammatory diseases.
Abivax has a program in clinical development with its lead drug candidate, obefazimod, to treat ulcerative colitis. Another program in Crohn’s disease is also in preparation and other potential inflammatory indications are being evaluated.
The company’s headquarters are based in Paris, France with a US office in Waltham, Massachusetts. Abivax’s Research and development work is conducted at its research center based in Montpellier, France. Wikipedia
Rreth Abivax SA
Drejtori ekzekutivMarc de Garidel | Hartmut J. Ehrlich
Punonjësit98
Themeluar më4 dhj 2013
Selia-
Sektori-
Uebsajtiabivax.com